Deferred Revenue (Tables)

12 Months Ended

Dec. 31, 2015

Deferred Revenue Disclosure [Abstract]

Deferred Revenue, by Arrangement, Disclosure

Deferred revenue consists of the following:

	As of December 31,
	2015		2014
Current portion:
Received or receivable from Sanofi (see Note 3a)	$	101,573	$	15,927
Received or receivable from Bayer HealthCare (see Note 3b)	24,290		33,652
Received for technology license agreement (see Note 4)	23,572		23,572
Other	4,052		874
	$	153,487	$	74,025
Long-term portion:
Received or receivable from Sanofi (see Note 3a)	$	582,664	$	62,819
Received or receivable from Bayer HealthCare (see Note 3b)	31,926		15,007
Received for technology license agreement (see Note 4)	33,851		57,423
Other	16,238		—
	$	664,679	$	135,249